Associations of an intron MMP9 polymorphism and the serum levels of gelatinase B with the development of COPD Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency Year: 2019
Correlation between a polymorphism in the promotor region of MMP3 (Stromelisyn-1) and the clinical-functional history in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 250s Year: 2001
Matrix metalloproteinase (MMP ) -1 and -3 promoter polymorphisms in Bulgarian patients with COPD Source: Annual Congress 2011 - Genetics of airway diseases and treatment Year: 2011
Circulating matrix metalloproteinase-9 (MMP-9) is associated with the extension of lung disease in patients with active tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 35s Year: 2004
The genetic polymorphism of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis Source: Annual Congress 2011 - Genetic and molecular background in pulmonary fibrosis Year: 2011
The role of genetic polymorphisms of glutation-S-transferase μ1 (GSTM1) and gelatinase B (MMP9) in the risk of COPD development Source: Annual Congress 2003 - Alpha-1 antitrypsin deficiency and COPD Year: 2003
Sputum matrix metalloproteinase-9 and tissue inhibitor of matrix metalloprotienase-1 levels in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006
Increased concentration of matrix metalloproteinase-9 in serum of COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 54s Year: 2005
The influence of cigarette smoke on the polymorphism of matrix metalloprotease (MMP2) in asthmatic patients Source: Annual Congress 2011 - New mechanisms in airway disease Year: 2011
Increased expression of MMP-2 in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 361s Year: 2005
Endothelium functional and vasomotor activity and collagen COL1A1 gene polymorphism in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 96s Year: 2005
Impact of -1562 C/T polymorphism of MMP9 gene on COPD susceptibility in Polish patients. Source: International Congress 2014 – Genetics and environmental factors underlying asthma and COPD Year: 2014
Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018
Association of MMP-1 polymorphisms with disease severity in Taiwanese patients with bronchiectasis Source: Eur Respir J 2007; 30: Suppl. 51, 130s Year: 2007
Association of -308G/A polymorphism of TNF gene with the activity of proteases and antiproteases in sputum in COPD patients Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases Year: 2008
Are there serum levels of MMP-2 and MMP-9 may be markers of COPD phenotypes? Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Matrix metalloproteinase (MMP) 12 is associated with clinical parameters of disease severity and exacerbations in asthma Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
Effects of glutation-S-transferase M1 (GSTM1) and T1 (GSTT1) and matrix metalloproteinase 9 (MMP9) on the decline of lung function in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 63s Year: 2004
Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 521s Year: 2001
Association of TNF, IL8, NOS1, NOS3 and NRAMP1 gene polymorphisms with COPD exacerbation etiology Source: Eur Respir J 2005; 26: Suppl. 49, 95s Year: 2005